Results 1 to 10 of about 1,055,803 (119)

Navigating second-line therapy after immunotherapy in advanced HCC☆Keypoints [PDF]

JHEP Reports
Summary: In recent years, systemic treatment options for hepatocellular carcinoma have expanded significantly, with pivotal phase III trials reporting unprecedented improvements in survival and response outcomes.
Arndt Vogel, Anna Saborowski, Lorenza Rimassa, Anthony El-Khoueiry   +3 more
doaj   +2 more sources

Рembrolizumab as second line therapy for hepatocellular patient

Медицинский совет, 2021
The optimal hepatocellular cancer (HCC) therapy remains a challenge. Due to checkpoint inhibitors patients with intolerance to the targeted therapy and or those with the impaired liver function can get an appropriate drug therapy.
I. A. Dzhanyan, V. V. Breder, O. I. Borisova, K. K. Laktionov   +3 more
doaj   +1 more source

Dolutegravir for second-line treatment: Programmatic implications of new evidence

Southern African Journal of HIV Medicine, 2022
No abstract available.
Ying Zhao, Gary Maartens, Graeme Meintjes   +2 more
doaj   +1 more source

Clinical and Immunological Outcomes after Initiation of Second Line Antiretroviral Therapy in People Living with HIV [PDF]

Journal of Clinical and Diagnostic Research, 2019
Introduction: Resistance to first-line Antiretroviral Therapy (ART) has been a major concern in People Living with HIV (PLHIV), which necessitates a switch to second-line therapy.
BASAVAPRABHU ACHAPPA, DEEPAK MADI, MOHAMMAD YOUSUFF, SATISH RAO, JOHN RAMAPURAM   +4 more
doaj   +1 more source

Update on the second-line treatment of infection: a narrative review

Therapeutic Advances in Gastroenterology, 2023
A standard bismuth quadruple therapy, a fluoroquinolone-containing triple (or quadruple) therapy or a proton pump inhibitor (PPI)-amoxicillin high-dose dual therapy has been recommended as a second-line treatment for Helicobacter pylori infection by the ...
Chih-An Shih, Chang-Bih Shie, Wei-Chen Tai, Seng-Kee Chuah, Hsi-Chang Lee, Ping-I Hsu   +5 more
doaj   +1 more source

Effect of therapy switch on time to second-line antiretroviral treatment failure in HIV-infected patients. [PDF]

PLoS ONE, 2017
Switch from first line antiretroviral therapy (ART) to second-line ART is common in clinical practice. However, there is limited knowledge of to which extent different reason for therapy switch are associated with differences in long-term consequences ...
Amanda Häggblom, Michele Santacatterina, Ujjwal Neogi, Magnus Gisslen, Bo Hejdeman, Leo Flamholc, Anders Sönnerborg   +6 more
doaj   +1 more source

Performance and Outcomes of Routine Viral Load Testing in People Living with HIV Newly Initiating ART in the Integrated HIV Care Program in Myanmar between January 2016 and December 2017

Tropical Medicine and Infectious Disease, 2020
Myanmar has introduced routine viral load (VL) testing for people living with HIV (PLHIV) starting first-line antiretroviral therapy (ART). The first VL test was initially scheduled at 12-months and one year later this changed to 6-months.
Sai Soe Thu Ya, Anthony D. Harries, Khin Thet Wai, Nang Thu Thu Kyaw, Thet Ko Aung, July Moe, Thurain Htun, Htet Naing Shin, Mar Mar Aye, Htun Nyunt Oo   +9 more
doaj   +1 more source

Second-line failure and first experience with third-line antiretroviral therapy in Mumbai, India [PDF]

Global Health Action, 2014
Background: There are limited data on the failure of second-line antiretroviral therapy (ART) and the use of third-line ART in people living with HIV in resource-limited settings.
Samsuddin Khan, Mrinalini Das, Aristomo Andries, Alaka Deshpande, Homa Mansoor, Peter Saranchuk, Petros Isaakidis   +6 more
doaj   +1 more source

Review: Second-line rescue therapy of infection

Therapeutic Advances in Gastroenterology, 2009
Helicobacter pylori infection is the main known cause of gastritis, gastroduodenal ulcer disease and gastric cancer. After more than 20 years of experience in H.
Javier P. Gisbert
doaj   +1 more source

Patterns of care for older patients with stage IV non‐small cell lung cancer in the immunotherapy era

Cancer Medicine, 2020
Background Historically, older patients with advanced lung cancer have often received no systemic treatment. Immunotherapy has improved outcomes in clinical trials, but its dissemination and implementation at the population level is not well‐understood ...
Kenneth L. Kehl, Michael J. Hassett, Deborah Schrag   +2 more
doaj   +1 more source